Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET

NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company
developing next-generation neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the Company will
release fourth quarter and full year 2018 financial results on Tuesday,
February 26, 2019 after the close of market. Revance will host a
corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET
on the same day to discuss the results and provide a business and
pipeline update.

Individuals interested in listening to the conference call may do so by
dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for
international callers and reference conference ID: 2298778; or from the
webcast link in the investor relations section of the company’s website

A replay of the call will be available beginning February 26, 2019 at
4:30pm PT/7:30pm ET to February 27, 2019 at 4:30pm PT/7:30pm ET. To
access the replay, dial (855) 859-2056 or (404) 537-3406 and reference
conference ID: 2298778. The webcast will be available in the investor
relations section on the company’s website for 30 days following the
completion of the call.

About Revance Therapeutics, Inc.

Revance Therapeutics is an emerging Silicon Valley biotechnology leader
developing neuromodulators for the treatment of aesthetic and
therapeutic conditions. Revance uses a unique proprietary peptide
excipient technology to create novel, differentiated therapies. The
company’s lead compound, DaxibotulinumtoxinA for Injection (RT002), is
in clinical development for a broad range of aesthetic and therapeutic
indications, including glabellar lines, cervical dystonia, plantar
fasciitis, upper limb spasticity and chronic migraine. RT002 has the
potential to be the first long-acting neuromodulator. The company is
advancing a robust pipeline of injectable and topical formulations of
daxibotulinumtoxinA. More information on Revance may be found at

“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.


Revance Therapeutics, Inc.:
Jeanie Herbert,
McClellan, Inc.:
John Grimaldi, 212-213-0006


General Media:
Mariann Caprino,
Nadine Tosk, 504-453-8344

error: Content is protected !!